Letermovir
- Generic Name
- Letermovir
- Brand Names
- Prevymis
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28F4N4O4
- CAS Number
- 917389-32-3
- Unique Ingredient Identifier
- 1H09Y5WO1F
- Background
Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors. Letermovir has recieved both priority and orphan drug status from the FDA. It is cur...
- Indication
Letermovir is indicated for prophylaxis against cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic hematopoietic stem cell transplant (HSCT) who are CMV-seropositive. It is also indicated for prophylaxis against CMV disease in adult kidney transplant recipients who are at risk (i.e. donor CMV-seropositive/recipient CMV-seronegat...
- Associated Conditions
- Cytomegalovirus (CMV) Infections
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.